Diagnostic Modality of Clostridioides difficile Infection Predicts Treatment Response and Outcomes in Inflammatory Bowel Disease
Authors:
- 23 March 2020
- journal article
- research article
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 66 (2) , 547-553
Abstract
Background Inflammatory bowel disease (IBD) patients are at increased risk of developing Clostridioides difficile infection (CDI). Common methods to diagnose CDI involve a combination of tests including the toxin A/B enzyme immunoassay (Toxin) and toxin gene polymerase chain reaction assay (PCR). Disease outcomes in Toxin+ versus Toxin-PCR+ IBD patients remain unclear. Aims This study aimed to examine the response to antibiotics and risk of IBD therapy escalation in Toxin+ versus Toxin-PCR+ patients. Methods IBD patients at an academic center with CDI diagnosis based on Toxin+ or Toxin-PCR+ from 2012 to 2017 were identified. Comparisons of response to antibiotics within 30 days and escalation of IBD therapy within 90 days of CDI diagnosis between these two groups were analyzed by Chi-square analysis. Multivariable regression analysis examined factors associated with antibiotic response. Results Among 92 patients included, 61% had Crohn’s disease and 39% had ulcerative colitis. 70% tested Toxin-PCR+. 60% received vancomycin or fidaxomicin to treat CDI. 82% of Toxin+ patients responded to antibiotics compared to 25% of Toxin-PCR+ patients (p < 0.001). 21% of Toxin+ patients required IBD therapy escalation compared to 63% of Toxin-PCR+ patients (p < 0.001). When adjusted for the types of antibiotics used, IBD subtypes, and immunosuppression status, positivity to Toxin (OR 14.85, CI 4.62–47.72) was the most significant predictor of response to antibiotics. Conclusions Toxin+ compared to Toxin-PCR+ IBD patients had a significantly higher rate of response to antibiotics and lower chances of requiring IBD therapy escalation. Future outcome studies involving CDI in IBD patients should be stratified by modality of diagnosis.Keywords
This publication has 20 references indexed in Scilit:
- Epidemiology, Diagnosis, and Management of Clostridium difficile Infection in Patients with Inflammatory Bowel DiseaseInflammatory Bowel Diseases, 2016
- Overdiagnosis ofClostridium difficileInfection in the Molecular Test EraJAMA Internal Medicine, 2015
- Burden ofClostridium difficileInfection in the United StatesNew England Journal of Medicine, 2015
- Diagnosis of Clostridium difficile Infection: an Ongoing Conundrum for Clinicians and for Clinical LaboratoriesClinical Microbiology Reviews, 2013
- Guidelines for Diagnosis, Treatment, and Prevention of Clostridium difficile InfectionsAmerican Journal of Gastroenterology, 2013
- Similar Outcomes of IBD Inpatients with Clostridium difficile Infection Detected by ELISA or PCR AssayDigestive Diseases and Sciences, 2013
- Impact of the Type of Diagnostic Assay on Clostridium difficile Infection and Complication Rates in a Mandatory Reporting ProgramClinical Infectious Diseases, 2012
- Decreased Diversity of the Fecal Microbiome in RecurrentClostridium difficile–Associated DiarrheaThe Journal of Infectious Diseases, 2008
- Reduction in diversity of the colonic mucosa associated bacterial microflora in patients with active inflammatory bowel diseaseGut, 2004
- Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoeaThe Lancet, 2001